Amphastar Pharmaceuticals, Inc. (AMPH) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AMPH Revenue Growth
Revenue Breakdown (FY 2025)
AMPH's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
AMPH Revenue Analysis (2014–2025)
As of May 8, 2026, Amphastar Pharmaceuticals, Inc. (AMPH) generated trailing twelve-month (TTM) revenue of $720.5 million, reflecting modest growth of +0.4% year-over-year. The most recent quarter (Q1 2026) recorded $171.2 million in revenue, down 6.5% sequentially.
Looking at the longer-term picture, AMPH's 5-year compound annual growth rate (CAGR) stands at +15.5%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $732.0 million in 2024.
Revenue diversification analysis shows AMPH's business is primarily driven by Epinephrine (100%). With over half of revenue concentrated in Epinephrine, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including LNTH (+0.6% YoY), PCRX (+4.6% YoY), and PRGO (-3.6% YoY), AMPH has underperformed the peer group in terms of revenue growth. Compare AMPH vs LNTH →
AMPH Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AMPHCurrent | $721M | +0.4% | +15.5% | 19.5% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 PCRX | $726M | +4.6% | +11.1% | 4.6% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% |
AMPH Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $719.9M | -1.7% | $356.1M | 49.5% | $140.4M | 19.5% |
| 2024 | $732.0M | +13.6% | $373.9M | 51.1% | $205.4M | 28.1% |
| 2023 | $644.4M | +29.1% | $351.1M | 54.5% | $197.0M | 30.6% |
| 2022 | $499.0M | +14.0% | $248.9M | 49.9% | $107.5M | 21.5% |
| 2021 | $437.8M | +25.1% | $199.7M | 45.6% | $69.9M | 16.0% |
| 2020 | $349.8M | +8.5% | $143.3M | 41.0% | $11.0M | 3.1% |
| 2019 | $322.4M | +9.4% | $131.9M | 40.9% | $-39,000 | -0.0% |
| 2018 | $294.7M | +22.7% | $107.0M | 36.3% | $-8,623,000 | -2.9% |
| 2017 | $240.2M | -5.9% | $90.8M | 37.8% | $-895,000 | -0.4% |
| 2016 | $255.2M | +1.4% | $104.2M | 40.8% | $15.7M | 6.1% |
See AMPH's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AMPH Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AMPH vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAMPH — Frequently Asked Questions
Quick answers to the most common questions about buying AMPH stock.
Is AMPH's revenue growth accelerating or slowing?
AMPH revenue growth slowed to +0.4%, below the 5-year CAGR of +15.5%. TTM revenue is $721M. The deceleration marks a shift from historical growth rates.
What is AMPH's long-term revenue growth rate?
Amphastar Pharmaceuticals, Inc.'s 5-year revenue CAGR of +15.5% reflects the variable expansion pattern. Current YoY growth of +0.4% is near this long-term average.
How is AMPH's revenue distributed by segment?
AMPH reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.